TNF and inflammatory bowel disease: Additionally, a 2020 systematic review and meta-analysis, which included 7,901 IBD patients treated with TNFα inhibitors and 135,370 biologic-naive patients, found no statistically significant link between TNFα inhibitors therapy and melanoma risk in IBD patients (pooled relative risk [pRR]: 1.20; 95% CI: 0.60–2.40) [17].